Life Sciences

Biomet under investigation for possible fraud

Device Regulation Alert: Safety, Compliance and Reimbursement News, April 27, 2009

Government investigators are examining allegations that Biomet improperly sold, promoted, and billed for its bone growth stimulation devices, the company disclosed in an April 14 SEC filing.

Federal authorities in West Virginia are investigating sales and marketing practices for Biomet’s subsidiary EBI, which makes electric stimulators for post-surgery patients. The U.S. Attorney in Massachusetts is also investigating possible improper conduct in the sale and leasing of the electrical-stimulation devices.

    ePharm5 InDepth
  • ePharm5 InDepth

    EPharm5 e-mail newsletter delivers the top 5 developments in pharma business innovation, with original research, interviews...

  • Medical Environment Update

    A subscription to Medical Environment Update pays for itself by saving you time sorting through complex regulations and...

  • Bloodborne Pathogens Training Video

    Meets OSHA requirements for training employees on the bloodborne pathogens standard!

  • Healthcare Marketing Advisor

    Healthcare Marketing Advisor provides concise, time-saving strategies for branding, promoting, and advertising your...

  • Needlestick Prevention Training Video

    Highlighting the five most frequent needlestick scenarios, this training video instructs frontline healthcare staff on on...

Most Popular